Soligenix Stock Today

SNGX Stock  USD 2.89  0.03  1.05%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 80

 
High
 
Low
High
Soligenix is trading at 2.89 as of the 30th of December 2024; that is 1.05 percent increase since the beginning of the trading day. The stock's open price was 2.86. Soligenix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 30th of November 2024 and ending today, the 30th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of June 1987
Category
Healthcare
Classification
Health Care
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.51 M outstanding shares of which 44.35 K shares are at this time shorted by private and institutional investors with about 1.15 trading days to cover. More on Soligenix

Moving together with Soligenix Stock

  0.82ME 23Andme HoldingPairCorr
  0.79VALN Valneva SE ADRPairCorr

Moving against Soligenix Stock

  0.77VCEL Vericel Corp OrdPairCorr
  0.75VCYT VeracytePairCorr
  0.74DRTS Alpha Tau MedicalPairCorr
  0.66DMAC DiaMedica TherapeuticsPairCorr
  0.64CDIOW Cardio DiagnosticsPairCorr
  0.64DSGN Design TherapeuticsPairCorr

Soligenix Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Chairman, CEO and PresChristopher Schaber
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Soligenix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Soligenix's financial leverage. It provides some insight into what part of Soligenix's total assets is financed by creditors.
Liquidity
Soligenix currently holds 3.49 M in liabilities with Debt to Equity (D/E) ratio of 2.44, implying the company greatly relies on financing operations through barrowing. Soligenix has a current ratio of 2.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Soligenix's use of debt, we should always consider it together with its cash and equity.

Net Income

(6.45 Million)
Soligenix (SNGX) is traded on NASDAQ Exchange in USA. It is located in 29 Emmons Drive, Princeton, NJ, United States, 08540 and employs 13 people. Soligenix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.25 M. Soligenix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.51 M outstanding shares of which 44.35 K shares are at this time shorted by private and institutional investors with about 1.15 trading days to cover. Soligenix currently holds about 20.16 M in cash with (8.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Soligenix Probability Of Bankruptcy
Ownership Allocation
About 97.35 % of Soligenix outstanding shares are held by general public with 0.02 (%) owned by insiders and only 2.63 % by institutional holders.
Check Soligenix Ownership Details

Soligenix Stock Institutional Holders

InstituionRecorded OnShares
Wells Fargo & Co2024-09-30
0.0
Goss Wealth Management Llc2024-06-30
0.0
Nomura Holdings Inc2024-06-30
0.0
Fmr Inc2024-09-30
0.0
Old National Bancorp2024-09-30
0.0
Ubs Group Ag2024-09-30
0.0
Vanguard Group Inc2024-06-30
0.0
Armistice Capital, Llc2024-09-30
0.0
Two Sigma Investments Llc2024-06-30
0.0
Stephens Inc2024-09-30
46.3 K
Geode Capital Management, Llc2024-09-30
18.4 K
View Soligenix Diagnostics

Soligenix Historical Income Statement

At this time, Soligenix's Interest Expense is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 10.6 M in 2024, whereas Depreciation And Amortization is likely to drop 6,226 in 2024. View More Fundamentals

Soligenix Stock Against Markets

Soligenix Corporate Management

Oreola DoniniChief Scientific Officer and Sr. VPProfile
Richard DunningEx OfficerProfile
CGMA CPACFO VPProfile
MSc MDSenior OfficerProfile

Additional Tools for Soligenix Stock Analysis

When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.